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Background: Heroin use among young women of reproductive age has drawn much attention around the world.
Although methadone is widely used in maintenance therapy for heroin/morphine addiction, the long-term effects
of prenatal exposure to methadone and preventative therapy remain unclear. For revealing this question, female
pregnant Sprague–Dawley rats were sub-grouped to receive (1) vehicle, (2) methadone 5 mg/kg at embryonic
day 3 (E3) and then 7 mg/kg from E4 to E20, (3) dextromethorphan (DM) 3 mg/kg, and (4) methadone + DM
(the rats received methadone followed by DM treatment), subcutaneously, twice a day from E3 to E20. The body
weight, natural withdrawal, pain sensitivity, ED50, conditioned place preference and water maze were conducted at
different postnatal stages (P1 to P79) of offspring. The quantitative real-time RT-PCR and electrophysiology were
also used to measure the gene expression of opioid receptors in the spinal cord and changes of LTP/LTD in the
hippocampus, separately.
Results: Prenatal exposure to methadone or DM did not affect survival rate, body weight, water maze and LTP
or LTD of offspring. However, prenatal methadone significantly increased the withdrawal symptoms, pain
sensitivity, addiction liability and decreased the mRNA expression of pain related opioid receptors. Co-administration
of DM with methadone in the maternal rats effectively prevented these abnormalities of offspring induced by
methadone.
Conclusions: Our study clearly showed that co-administration of dextromethorphan with methadone in the
maternal rats prevented the adverse effects induced by prenatal methadone exposure. It implies that dextromethorphan
may have a potential to be used in combination with methadone for maintenance treatment in pregnant heroin-addicted
women to prevent the adverse effects induced by methadone on offspring.
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Abuse of opioids causes serious social and health
problems around the world. Methadone is a synthetic
mu- (μ-) opioid receptor agonist that has been used
for maintenance therapy in heroin addicts (including
pregnant women) for more than 40 years [1]. Although* Correspondence: pltao@nhri.org.tw
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unless otherwise stated.methadone has been shown to be effective in redu-
cing withdrawal symptoms and impulsive injection of
opioids [2], chronic use of methadone has also exhib-
ited addictive liability and respiratory depression in
some subjects [3]. Recently, an U.S. report showed
that 4.4% of pregnant women used illicit drugs in
2009–2010 [4]. This finding has drawn much atten-
tion to this population; and the effects of intrauterine
drug exposure on offspring are noticed to be urgent. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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addicted to opioids (such as heroin and morphine)
have been known to suffer from higher mortality and
problems with the central nervous system including
dysfunction of intellectual ability or emotional con-
trol [5,6]. In addition, chronic morphine exposure
during adolescence of female rats caused transge-
nerational effects on anxiety-like behavior and morphine-
induced sensitization in the offspring [7]. Our previous
studies suggest that offspring, if exposed to opioid
prenatally, may experience long-term effects on be-
haviors and biochemical homeostasis [8]. This indi-
cates that understanding the effects of prenatal opioid
exposure on offspring and finding prevention and
treatment strategies are important. Methadone is not
only a synthetic μ-opioid receptor agonist but also an
antagonist for N-methyl-D-aspartate (NMDA) recep-
tor, with the majority of the μ-opioid receptor agonist
activity residing in the R-isomer [9]. Methadone is
also commonly utilized in detoxification and main-
tenance programs for heroin-addicted patients, in-
cluding pregnant women [1,10]. Some clinical studies
of methadone exposure in the pregnancy stage have
found that the increase in the incidence of mortality,
decrease of birth weight ranges, low head circumfer-
ence, and mood, attention and cognitive deficits in
the methadone-exposed infants as compared to drug-free
control [11-13]. Additionally, the neonatal abstinence
syndrome (NAS) is characterized to high-pitched cry-
ing, hyperactive reflexes, tremors, hypertonicity, con-
vulsions, regurgitation, dehydration, diarrhea etc. [13].
These symptoms are like to the withdrawal syn-
dromes in the rodents. The incidence of NAS in the
newborn from MMT mother is typically 60-90%; a
large of them presented severe withdrawal and need
the pharmacotheraputic intervention [13]. Further-
more, the NAS increases the risk of mortality if it is left
untreated [14]. The doses of methadone used for treat-
ment of heroin addicts are wide ranges (50–100 mg/daily)
[15], some cases are even closed to 200 mg/daily in
previous reports and observation in our cohort [16,17].
Several studies suggested that the score of NAS, per-
centage of treatment for withdrawal, and duration of
neonatal hospitalization were positively associated
with maternal methadone dosage [18-20]. This may
indicate that higher maternal methadone doses cause
severe NAS. However, the issue of maternal metha-
done dose versus the prognosis of NAS remain unre-
solved, that may due to the inability to appropriately
control for numerous confusing factors, such as the
health status, personal neglect, poor antenatal care
[13]. No matter what these findings provided, a con-
cept that an investigation of possible strategies for re-
ducing the dosage of methadone of maternal use orusing a combination of some medicine may be helpful
in decreasing adverse effects (mortality, weight gain,
or NAS etc.) on offspring that were prenatally ex-
posed to methadone.
Dextromethorphan (DM), a commonly used anti-
tussive agent, is without opioid-like activity [21].
Both DM and its major metabolite dextrophan are
NMDA receptor antagonists. DM has also been reported
to treat neurologic diseases, such as non-ketotic
hyperglycinemia and intractable seizure in neonates
[22,23]. Results from the epidemiologic analysis of
prenatal exposure of therapeutic dose of dextrome-
thorphan (117.2 mg, the maximum dose is 120 mg/daily
with 30 mg for 4 times [15]) showed no evidence of
teratogenicity in infants [24]. Studies have shown that
DM reduced morphine reward as measured by CPP
test, and this might be related to DM’s antagonizing
effect on NMDA receptors that are involved in the
activation of mesocorticolimbic dopaminergic sys-
tems [25,26]. Our previous studies also demonstrated
that co-administration of DM with morphine during
pregnancy and throughout lactation reduced several
morphine-induced adverse effects [27,28] and could
prevent higher vulnerability to inflammatory thermal
hyperalgesia in rat offspring [29].
Although methadone is also a μ-opioid agonist like
morphine, the effects of DM in prenatally methadone-
exposed offspring have not been explored. Therefore, in
the present study, we aimed to investigate if the prenatal
co-administration of DM with methadone prevents or de-
creases the possible adverse effects induced by methadone
on the offspring, such as withdrawal symptoms, changes




Pregnant Sprague–Dawley rats (BioLASCO Taiwan
Co., Taipei, Taiwan) and their offspring were used in
this study. All animals were housed in an animal
room with a 12-h light/dark cycle (light on 07:00–
19:00), a temperature of 25°C, and humidity of 50 ±
10%. Pregnant rats were kept individually in separate
cages, and their male offspring were housed 2–3 per
cage after weaning. A diet (Prolab 2500 Rodent 5P14,
LabDiet, PMI Nutrition International, St. Louis, MO,
USA) and water were provided ad libitum. The care
of animals was carried out in accordance with institu-
tional and international standards (Principles of La-
boratory Animal Care, NIH); the animal protocol was
approved by the IACUC of the National Health Re-
search Institutes (NHRI-IACUC-099087-A). All ex-
periments were performed following the schedule
below.
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Methadone HCl (USP, Maryland, MD, USA) or dextro-
methorphan HBr (Sigma Aldrich, St. Louis, MO, USA)
were dissolved in sterilized distilled water and were ad-
ministered subcutaneously (s.c.) in a volume of 1.0 ml/kg
of body weight.Prenatal treatment
Pregnant Sprague–Dawley rats, weighting 200–250 g
(10–12 weeks old), were assigned to four groups ran-
domly. Each group was s.c. injected with either vehicle
or drug(s) during the gestational period (E3–E20). Vehicle
control group rats received distilled water, 1 ml/kg (s.c.),
twice a day. Methadone-group rats received 5 mg/kg at E3
and then 7 mg/kg from E4 to E20 (s.c), twice a day. DM
group rats received 3 mg/kg of DM (s.c.), twice a day. In
the methadone + DM group, the rats received methadone
followed by DM treatment twice a day. The offspring were
weaned at day 28 after birth and housed 2–3 per cage
after weaning until use. The offspring from the same
dam were randomly assigned to different experiments
to avoid the litter effect (the female offspring were not
used in this study).Determination of natural withdrawal behaviors
Natural withdrawal behaviors of the offspring were ob-
served for 15 min within 24 h after birth. One pup was
chosen randomly and removed from the dam before be-
ing placed on a white filter paper. Head moves, moving
paws, rolling, stretching, twisting, and walking behaviors
were observed and counted for 15 min. There were at
least 11 pups in each group.Determination of pain sensitivity of offspring on p30 and
p60
Tail-flick test: A light beam was focused on an animal’s
tail until that the rat flicked its tail. The recorded time
was a measure of the pain threshold. The tail-flick ap-
paratus (Columbus Instrument, Columbus, OH, USA)
was used in the study. The basal latency of most ratswas around 3–3.5 sec; a cutoff time of 10 sec was used
to avoid tissue damage.
Hot-plate test: In this study, a hot-plate apparatus
(IITC Life Science Inc., Woodland Hills, CA, USA) was
used. The animal was placed on the hot plate and the
time was measured until the animal started to shake or
lick its hind paw or jump from the hot plate. To avoid
tissue damage, the animal was removed immediately
from the metal surface after it showed pain-related be-
havior or reached the cutoff time (30 sec).
Determination of ED50 and degree of tolerance after
sub-chronic treatment of’ methadone in adult offspring
The ED50 value was used as an index of the antinocicep-
tive effect of methadone and this was determined by the
up-down method [30] with the tail-flick method. Details
were shown in the Additional file 1. The degree of toler-
ance was defined as the ratio of ED50 after sub-chronic
treatment of methadone (4 mg/kg, s.c., b.i.d. for 6 days)
(day 79) and ED50 before CPP experiment and sub-
chronic methadone treatment (day 61).
Determination of the rewarding effect of methadone in
adult offspring by conditioned place preference (CPP) test
In this study, we used the CPP test to evaluate methadone-
induced reward in the adult male offspring (p64-p71).
Details are shown in the Additional file 1. For CPP
conditioning, each rat was given saline in the morning
and put in one chamber of the CPP box for 40 min
and was given drug (methadone, 4 mg/kg, s.c.) in the
afternoon and put in another chamber of the CPP box
for 40 min everyday for 6 days. CPP tests were performed
and recorded for 15 min on the day before and the day
after conditioning for 6 days.
Water maze test
The water maze was circular, had a diameter of 180 cm
and a depth of 60 cm, and was filled with water (21–23°C)
to a depth of 40 cm. Spatial cues were located on the
walls. The total pool was divided into 4 quadrants (NE,
SE, SW, NW), which were designated as zones 1–4,
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surface of the water) was placed in the zone 1 area (NE
quadrant). Rats received 5 days of training for two trials
per day. The time for the animal to find the platform was
recorded, and the maximal duration for each trial was 60
sec; then the animal was put on the platform for 10 sec to
allow the animal to look around. On day 6, the platform
was removed and the time the animal spent in zone 1, the
previous location of the platform, was determined. All pa-
rameters were automatically recorded and analyzed by
video tracking software (Etho vision, Noldus, Leesburg,
VA, USA).
Hippocampal LTP and LTD determination by
electrophysiology
The details of the electrophysiology recording protocol
are described in the Additional file 1. Briefly, transverse
350-μm-thick hippocampal slices were prepared from
p14-p21 male offspring using a commercial vibratome
(DTK-1000, Dosaka, Kyoto, Japan). Tungsten bipolar
electrodes (FHC, Bowdoin, ME, USA) were placed in the
stratum radiatum of the hippocampal CA1 region to
stimulate the Schaffer collateral pathway directly. Field
excitatory postsynaptic potentials (fEPSPs) were recorded
and analyzed offline. After 30 min of stable baseline re-
cording, a high-frequency stimulation (HFS, consisting of
two trains of 100 Hz bursts, 1 s in duration and with a 1
min span between the two trains) or a low-frequency
stimulation (LFS, 1 Hz for 15 min) was applied to Schaffer
collaterals to induce long-term potentiation (LTP) or
long-term depression (LTD) of EPSPs, respectively.
Determination of expressions of mRNAs by quantitative
real time RT-PCR (qPCR)
Details of qPCR protocol are described in the Additional
file 1. Briefly, total RNA was extracted from spinal cord
tissue samples using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA). First-strand cDNA was synthesized from 1 μg
of the total RNA with an iScriptTM cDNA Synthesis Kit
(Bio-Rad Laboratories, Hercules, CA, USA). The SYBR
green system (SsoFastTM EvaGreen, Bio-Rad) was used to







Reverse TCCACGACATACTCAGCACNOP receptor (Oprl1) (designed by Beacon Designer 7.6
[PREMIER Biosoft, Palo Alto, CA, USA] with NCBI
reference sequence NM_031569.3), μ-opioid receptor
(Oprm1) and glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) (housekeeping gene) are presented in Table 1.
A three-step run protocol was used: (i) 1 sec at 98°C;
(ii) quantification program repeated 40 times (1 sec at
98°C; 10 sec at 57°C); (iii) melting curve program (70–93°C
with a heating rate of 0.5°C per 10 sec). The Ct value of each
gene was normalized with their Gapdh. ΔΔCt = ΔCt (target
genetreat- GAPDHtreat)-ΔCt (Controlcontrol-GAPDHcontrol).
The fold change was measured as 2−ΔΔCt.
Statistical analysis
Data are expressed as mean ± SEM. Student t-test, one-
way or two-way ANOVA, repeated measures one-way
ANOVA, and the Newman-Keuls test or Bonferroni
post-tests were used to analyze the data. A difference
was considered to be significant if p < 0.05.
Results
Prenatal exposure to methadone or DM did not influence
the survival rate or body weight of offspring
As shown in Figure 1A, the survival rate of offspring on
day 7 after birth for the methadone, DM, and metha-
done + DM groups did not differ significantly from the
control group (F(3,27) = 3.19; p = 0.08). The litter sizes in
all tested groups were not significantly different in current
study. Similarly, the body weights of all tested groups at
p14 (F(3,28) = 0.47; p = 0.71), p30 (F(3,34) = 2.30; p = 0.09),
and p60 (F(3,34) = 0.006; p = 0.999) showed no significant
difference (Figure 1B). These results indicate that prenatal
exposure to methadone, DM, or methadone + DM at the
doses in the current study did not change the survival or
growth rate of offspring.
Prenatal co-administration of DM with methadone prevented
the increase of natural withdrawal behaviors of offspring
within 24 h after birth
Natural withdrawal behaviors of the offspring were shown
on Table 2. We found that the total counts of natural
withdrawal symptoms were significantly higher in thePosition Product (bp) Reference
268–360 93 Designed by software
447–521 75 [59]
169–359 191 [60]
Figure 1 Prenatal exposure to methadone did not affect the survival rate and body weight. (A) The survival rate of offspring on day 7 after
birth or (B) the body weight at different ages of male offspring. Data are presented as mean ± S.E.M. (n ≥ 8).
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group (17.3 ± 4.0). Co-administration of DM with
methadone reduced these natural withdrawal symp-
toms to 38.3 ± 4.2, which was not significantly different
from that of the control group. Surprisingly, prenatal ex-
posure to DM alone also increased the natural withdrawal
symptoms in offspring to 60.5 ± 14.0, as shown on
Table 2.Table 2 Natural withdrawal behaviors of offspring within 24
Control Me
Natural withdrawal symptoms
Head moves 10.6 ± 2.5 22.8
Paws moving 1.7 ± 0.2 44.8
Stretching 0.0 ± 0.0 0.0
Twisting 4.6 ± 1.7 3.2
Rolling 0.4 ± 0.4 0.8
Walking 0.0 ± 0.0 0.17
Total score 17.3 ± 4.0 71.8
Natural withdrawal behaviors of the offspring were observed and counted for 15 m
way ANOVA and Newman-Keuls test were used to analyze the data. *P < 0.05, **p <
to the methadone group.Prenatal methadone exposure increased the pain
sensitivity of offspring, and co-administration of DM with
methadone prevented this effect
Prenatal methadone-exposure significantly decreased the
pain threshold of offspring determined by either tail-flick
(Figure 2A) or hot-plate test (Figure 2B) on p30 (F(3,31) =
5.00; p < 0.05) or p60 (F(3,29) = 2.85; p < 0.05). Prenatal
exposure to DM did not alter the pain threshold ofh after birth
thadone Methadone + DM DM
Count (Mean ± SEM)
± 6.7 23.3 ± 2.9 44.3 ± 11.1**
± 12.5*** 8.2 ± 2.6## 14.1 ± 4.0##
± 0.0 0.0 ± 0.0 0.17 ± 0.17
± 1.1 6.8 ± 1.4 0.8 ± 0.5
± 0.5 0.0 ± 0.0 1.3 ± 1.0
± 0.17 0.0 ± 0.0 0.0 ± 0.0
± 17.8* 38.3 ± 4.2 60.5 ± 14.0*
in within 24 h after birth. Data are presented as mean ± S.E.M. (n ≥ 11). One-
0.01, and ***p < 0.001, compared to the control group; ##p < 0.01, compared
Figure 2 The effects of pain threshold in prenatal drug exposure male offspring. Prenatal exposure to methadone (MD) decreased the pain
threshold at different ages (p30 or p60) in male offspring and prenatal co-administration of methadone and dextromethorphan (MD + DM)
prevented this effect. Acute heat nociceptive responses were determined by (A) tail-flick test and (B) hot-plate test. Data are presented as
mean ± S.E.M. (n ≥ 8). *P < 0.05 and **p < 0.01 when compared to the control group.
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DM in conjunction with methadone from E3-E20, pre-
vented the changes induced by prenatal methadone ex-
posure alone either partially or completely in the tail
flick and hot plate tests, respectively.
The mRNA levels of pain-related receptors in the spinal
cord of male offspring
In order to reveal the possible mechanisms by which pre-
natal methadone affects pain sensitivity, we investigated
the gene expression of μ-opioid receptors (MOR) and
nociceptin/orphanin FQ receptors (NOPR) in the spinal
cord of male offspring. Our results showed that prenatal
exposure to methadone caused a significant decrease in
the gene expression (mRNA level) of MOR (F(3,28) =
56.35; p < 0.001) and NOPR (F(3,28) = 60.53; p < 0.001)
(Figure 3A and B). In the results of prenatal exposure to
DM alone, there were also slight but significant de-
creases in the mRNA levels of MOR and NOPR. How-
ever, co-administration of DM with methadone in the
maternal rats significantly prevented the decrease in
mRNA levels of these two pain-related receptors in the
spinal cord of offspring induced by prenatal metha-
done exposure.Rewarding effects of methadone in male adult
offspring
The CPP test was used to determine the rewarding effect
of methadone in the offspring. We found that when
methadone (4 mg/kg, s.c.) was given once daily and condi-
tioned for 6 days, it significantly increased the preference
time for the drug-paired compartment in all groups tested
(F(3,68) = 6.59; p < 0.001) (post-condition vs. pre-condition,
Figure 4). However, methadone-induced CPP in the pre-
natal methadone-exposed group was significantly higher
than that of the control group. Co-administration of DM
with methadone in the maternal rats significantly pre-
vented this higher rewarding effect and the higher addic-
tion potential of methadone in the offspring, as shown in
Figure 4 (F(3,34) = 11.89; p < 0.001).
Sub-chronic treatment with methadone in offspring
induced tolerance, which was not affected by prenatal
co-administration of DM with methadone
According to the results shown in Figure 2, prenatal
exposure of methadone decreased the pain threshold
(i.e. increased the pain sensitivity). In this study, the
methadone-induced tolerance was measured in off-
spring of all groups. As shown on Table 3, the ED50 of
Figure 3 The mRNA expression of pain-related opioid receptors in the spinal cord of offspring. The mRNA level of (A) mu-opioid receptor
(MOR); and (B) nociceptin receptor (NOPR); in the spinal cord of prenatal drug(s) exposed male offspring at P30. Data are presented as mean ± S.E.M.
(n ≥ 8). *P < 0.05, **p < 0.01 and ***P < 0.001 when compared to the control group; ###p < 0.001 when compared to the methadone (MD) group.
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(1.58–1.77 mg/kg). After the CPP experiment and sub-
chronic treatment of methadone, the ED50 of all the
groups increased 1.34–1.84-fold, as shown on Table 3.
However, there were no significant differences among
the groups regarding the ED50 after sub-chronic metha-
done administration.
Prenatal exposure with methadone or DM did not
influence the spatial memory of male offspring, as
determined by the water maze test
A water maze was utilized to test the spatial learning
and memory in prenatal methadone-exposed offsprings.We found no difference in the water maze test among all
groups tested (Figure 5A and B). As shown in Figure 5A,
the learning rate during the five days of training was simi-
lar (F(3,325) = 0.66; p = 0.9226) and there was also no sig-
nificant difference for time spent in the platform quadrant
(without platform) on day 6 (F(3,65) = 0.89; p = 0.45)
(Figure 5B) in all groups. Long-term potentiation (LTP)
and long-term depression (LTD) were determined for
the possible neuronal mechanisms of memory forma-
tion using hippocampal slices of prenatal methadone-
or vehicle-exposed offspring (p14-p21). As shown in
Figure 6, there was no significant difference between
these two groups for LTP (p = 0.511) or LTD (p = 0.753).
Figure 4 Postnatal methadone-induced rewarding effects on prenatal methadone or DM exposed offspring. Rewarding effects induced
by methadone (MD, 6 conditioning at 4 mg/kg, s.c.) in male adult offspring. Data are presented as mean ± S.E.M. (n ≥ 8). *P < 0.05 and ***p < 0.001
when compared to pre-conditioning data of its own group; ###p < 0.001 when compared to post-conditioning data of the control group.
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The goal of this study is to evaluate the effects of co-
administration of DM with methadone in the prenatal
stage on offspring [21,29,31]. The doses we used are
within the clinical therapeutic ranges converted to rats
based on the body surface area. Seven mg/kg methadone
for rats is approximately 70 mg methadone for 70 kg hu-
man; and 3 mg/kg DM for rats is about 30 mg for 70 kg
human. In the present study, the findings indicate that
DM treatment with methadone in the prenatal stage
could prevent or suppress methadone-induced behav-
ioral abnormality in the offspring. Furthermore, the ef-
fects of prenatal exposure to methadone to decrease the
mRNA levels of MOR and NOPR in the spinal cord of
offspring were also prevented by co-administration of
DM with methadone in the maternal rats. Prenatal
methadone did not affect learning or spatial memory in
the offspring or the LTP or LTD of hippocampal slices
of the prenatal methadone-exposed offspring.
The survival rate and body weights of offspring in
methadone group were not different from those of the
vehicle control group. Prenatal exposure to DM or
methadone + DM at the doses we used did not change









Control 1.77 ± 0.13 2.46 ± 0.13** 1.34
Methadone 1.77 ± 0.13 3.08 ± 0.13*** 1.74
Methadone + DM 1.78 ± 0.13 3.28 ± 0.18*** 1.84
DM 1.58 ± 0.18 2.46 ± 0.13* 1.56
Tail-flick test and up-down method were used to determine the ED50. Data are
presented as mean ± S.E.M. (n ≥ 6). Two-way ANOVA and Bonferroni post-tests
were used to analyze the data. *P < 0.05, **p < 0.01, and ***p < 0.001, compared
to the data before CPP of its own group.Furthermore, we did not observe the dams in the
groups behaving abnormally during their pregnancy or
breeding period. These results may rule out the pos-
sible effects of nutrition, doses of methadone, and ma-
ternal care on the behavioral changes of offspring.
Therefore, the preventive effects of DM on prenatal
methadone-induced behavioral or biochemical changes
could be explained by its pharmacologic actions.
The changes in pain sensitivity in prenatal methadone-
exposed animals might be because methadone changes
the expression of opioid receptors. MOR and NOPR are
expressed early in the brain and spinal cord at the em-
bryonic stage [32,33]. These findings suggest that MOR
and NOPR may be easily influenced by prenatal opioid
exposure. Besides, the expressions of opioid receptors in
the central nervous system may exhibit a region specific
character in the intrauterine opioid-exposed animals. An
early study showed that prenatal methadone administra-
tion induced sustained decreases in the expression of
both delta- (δ-) and μ-opioid receptors in the hypothal-
amus but not in the cerebral cortex [34]. Another study
by Darmani et al. [35] exhibited non-significant changes
in the expression of MOR, but reducing its binding af-
finity to methadone in the whole brain homogenate of
prenatal methadone-exposed rat offspring. Recently, Chiang
et al. [36], also showed that expressions of MOR and NOPR
were not different in the nucleus accumbens of prenatal
methadone-exposed rats at their adulthood as compared
with their control mates. In the current study, we found a
significant decrease in the mRNA expression of MOR and
NOPR in the spinal cord of prenatal methadone-exposed
offspring at p30 and meanwhile, the pain sensitivity of off-
spring is increased. It has been know that the peptide of
nociceptin/orphanin FQ (N/OFQ) acts on the NOPR and
also serves as a pain modulator in the central nervous
system [37]. N/OFQ and NOPR are highly presented
in the dorsal part of the spinal cord [37,38] and the
pain-modulated function of N/OFQ in spinal cord is
Figure 5 The effects of prenatal drug exposure on spatial learning and memory of male offspring. Prenatal exposure to methadone did
not affect spatial learning and memory of male offspring determined by water maze test. (A) Water maze training with platform from day 1 to
day 5; (B) water maze test without platform on day 6. Data were presented as mean ± S.E.M. (n ≥ 12).
Figure 6 Changes of LTP and LTD in the prenatal methadone- or DM-exposed offspring. Prenatal methadone did not change the
hippocampal LTP or LTD in p14-p21 rats. Time courses of normalized slopes of fEPSPs during (A) LTP and (B) LTD experiments are shown.
A high-frequency stimulation (HFS) protocol (A) or a low-frequency stimulation (LFS) protocol (B) was applied at 0 min (arrow) to hippocampal
slice of p14-p21 offspring born from control (black circle, n ≥ 8) or methadone (hollow circle, n ≥ 7) treated maternal rats. Representative traces of
fEPSP from one control slice before HFS (1) and 55 min after HFS (2) are shown in the top middle of (A), and another representative traces of fEPSP
from one control before (1) and 60 min after (2) LFS are shown in the top middle of (B). Scale bar, 100 μV, 10 ms.
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Endorphins can act on the MOR and produce antinoci-
ceptive function in the spinal cord [40]. Early studies also
showed that intrathecal administration of N/OFQ causes
the antinociceptive effect in the monkey and rodents
[37,38]. Both of MOR and NOPR could be influenced on
expression or affinity by chronic administration of exogen-
ous opioids [41,42]. Several studies have been shown to
cross influence another type of opioid receptors when
continued activation of one type of opioid receptors. For
example, chronic treatment with kappa- (κ-) opioid recep-
tor agonist, U50,448H, decreased the expression of both
κ- and δ- opioid receptors in the spinal cord and striatum
of rats [43]. It has also been shown that chronic morphine
influenced the N/OFQ systems [42,44]. Previous studies
also provided evidence that NOPR and MOR not only
formed a heterodimer with each other, but also regulated
the desensitization function with each other [45-47].
Formation of NOPR/MOR heterodimer selectively in-
duced cross-desensitization of MOR and impaired the po-
tency of DAMGO-induced adenylate cyclase inhibition
and p42/p44 (MAPK) phosphorylation [46]. Furthermore,
Mandyam et al. [45] found that the PKC signals may be a
cross-talk mechanism for NOPR/MOR heterodimer.
On the other hand, although our results showed that
the mRNA of NOPR and MOR were also reduced in the
spinal cord of prenatal DM-exposed rats, the pain sensi-
tivity did not show significant change in this group of
animals. These results imply a complicated cross-talk of
cellular signaling to behavioral expression and need fur-
ther exploration. In a brief summary, the increase of
pain sensitivity in the prenatal methadone-exposed ani-
mals may be partly due to the reduction of both NOPR-
and MOR-related signals.
Besides pain regulation, prenatal opioid-exposed off-
spring might also change their reward sensitivity to opi-
oids, such as offspring from morphine-addicted mother
becoming more sensitive to morphine-induced reward
[48,49]. In this current study, prenatal methadone-exposed
offspring showed higher reward than offspring from other
groups after conditioning with 4 mg/kg methadone for
6 days. This implies that the offspring from methadone-
treated mothers may more easily become addicted to
methadone later in their life than others.
Several studies have found that the NAS of offspring
was related to the dose of methadone used in the
mother [18,19,50]. A higher dose of methadone exposure
in prenatal stage caused more serious NAS and in-
creased frequency of morphine treatment in the hospital.
The doses of methadone we used in the present study
also induced certain natural withdrawal behaviors but
not very serious (only “paws moving”). We also found
that prenatal exposure to DM alone also increased natural
withdrawal behaviors slightly. However, co-administrationof DM with methadone in the maternal rats reduced these
natural withdrawal behaviors of neonates to similar scores
of the control group (Table 2).
Recently, the relationship between NMDA receptors
and opioid systems has been studied. Morphine toler-
ance could be attenuated by resveratrol via inhibiting
neuroinflammation and down-regulating the expression
of NR1 and NR2B subunit of NMDA receptors [51].
Morphine-induced up-regulated state of NR3B in lym-
phocytes could also be reduced after subjects entered a
methadone maintenance program [52]. This indicates
that NMDA receptors play an important role to regulate
opioid-induced effects and are involved in the opioid-
addiction process in both humans and animals [53].
Since both methadone (racemic mixture) and DM have
been shown to have NMDA receptor antagonist prop-
erty [9,21], we think that blocking of NMDA receptors
by methadone or DM may be involved in the increase of
natural withdrawal behaviors of offspring. There was a
human case report which showed DM caused with-
drawal syndromes with over 10 folds (1800 mg/daily) of
therapeutic dose [54]. However there is no evidence
showed that the NAS has exhibited in prenatal-exposed
infants within the therapeutic dose ranges of DM.
Compared with our previous prenatal morphine-exposed
studies [28,31], methadone seems to show less adverse ef-
fects than morphine in these intrauterine exposed rats.
This may be due to the NMDA receptor antagonist prop-
erty of methadone. Chronic morphine administration af-
fected the binding properties and EPSCs of NMDA
receptors in the hippocampus of offspring [31,55]. It has
also been shown that prenatal exposure to morphine leads
to memory problems in offspring [56-58]. However, no
change regarding the spatial memory or hippocampal LTP/
LTD was found in prenatal methadone-exposed rats in the
current study. Although suppression of NMDA receptor
activities could influence the development of neurons,
over-activation of the NMDA receptors through chronic
activation of opioid system may also cause serious neuro-
toxicity in offspring or lead to other defects in them. The
excess activity of NMDA receptors induced by chronic opi-
oid (morphine or methadone) may be counterbalanced by
DM or methadone itself, so that the preventative effects of
DM and less-adverse effects of methadone upon the
offspring could be seen. In fact, offspring exposure to
DM alone in the intrauterine stage decreased the mRNA
expressions of MOR and NOPR in the spinal cord, which
may also be due to blocking of the normal function of
NMDA receptors.
Conclusion
In summary, this study showed that co-administration of
DM with methadone in the maternal rats significantly
decreased the effects of prenatal methadone on pain
Chiang et al. Journal of Biomedical Science  (2015) 22:19 Page 11 of 12sensitivity, natural withdrawal, and reward in the off-
spring. In conclusion, this study reveals that DM may
have great potential to be used in combination with
methadone maintenance therapy in pregnant heroin abusers
to reduce the side effects of methadone on the offspring.
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